ETHACRYNATE SODIUM FOR INJECTION POWDER FOR SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
30-07-2018
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
ETHACRYNIC ACID (ETHACRYNATE SODIUM)
Tillgänglig från:
ENDO PAR INNOVATION COMPANY, LLC
ATC-kod:
C03CC01
INN (International namn):
ETACRYNIC ACID
Dos:
50MG
Läkemedelsform:
POWDER FOR SOLUTION
Sammansättning:
ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50MG
Administreringssätt:
INTRAVENOUS
Enheter i paketet:
50ML
Receptbelagda typ:
Prescription
Terapiområde:
LOOP DIURETICS
Produktsammanfattning:
Active ingredient group (AIG) number: 0101703001; AHFS:
Bemyndigande status:
CANCELLED PRE MARKET
Tillstånd datum:
2023-07-07
Produktens egenskaper
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
ETHACRYNATE SODIUM FOR INJECTION
House Std.
_ _
Lyophilized powder for injection, 50 mg equivalent to ethacrynic
acid
Intravenous
Saluretic-Diuretic Agent
Endo Par Innovation Company, LLC
6 Ram Ridge Road, Chestnut Ridge,
New York 10977, USA
Imported/Distributed by:
Paladin Labs Inc.
100 Alexis Nihon Blvd., Suite 600
Saint-Laurent, Quebec, Canada
H4M 2P2
Date of Preparation:
July 30, 2018
Version 1.0
Submission Control No: 209656
_Product Monograph_
_Page 2 of 20_
_Ethacrynate Sodium for Injection_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
......................................................................................................
5
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
......................................................................................................
7
DRUG INTERACTIONS
......................................................................................................
8
DOSAGE AND ADMINISTRATION
..................................................................................
9
OVERDOSAGE
...................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................... 10
STORAGE AND STABILITY
............................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
..........................................................................
11
DOSAGE FORMS, COMPOSITION AND
PACKAGING................................................ 11
PART
Läs hela dokumentet
